Increased frequency of repeat expansion mutations across different populations

INTRODUCTION

Repeat expansion disorders (REDs) are a heterogeneous group of conditions which mainly affect the nervous system, and include Fragile X syndrome, the commonest inherited form of amyotrophic lateral sclerosis and frontotemporal dementia (C9orf72-ALS/FTD)¹, and inherited ataxias (Friedreich ataxia (FA), and RFC1-Cerebellar Ataxia, Neuropathy, Vestibular Areflexia syndrome, CANVAS²). REDs are caused by the same underlying mechanism: the expansion of short repetitive DNA sequences (1-6 bp) within their respective genes. The mutational process is gradual: normal alleles are usually passed stably from parent to child with rare changes in repeat size; intermediate-size are more likely to expand into the disease range, giving rise to pathogenic repeat lengths in the next generation. Repeat lengths are classified in ascending order as normal, intermediate, premutation, reduced penetrance, or full mutations, though this classification is not universal, and not all RED loci have well-defined ranges for intermediate or reduced penetrance range.

REDs are clinically heterogeneous: for example, C9orf72 expansions can present as either FTD or ALS even within the same family; and one in three patients carrying the repeat expansion in C9orf72 shows an atypical presentation at onset such as Alzheimer’s and Huntington’s disease (HD) among others^3,4. For many REDs, the variability in repeat lengths underlines the substantial clinical heterogeneity⁵, longer repeats cause more severe disease, and earlier symptom onset⁶.

Previous studies have estimated that REDs affect 1 in 3,000 people⁷. Despite their broad distribution in human populations, few global epidemiological studies have been performed. In these studies, prevalence estimates are either population-based, in which affected individuals are identified based on clinical presentation, or genetically tested based on the presence of a relative with a RED. Given that one of the most striking features of REDs is that they can present with markedly diverse phenotypes, REDs can remain unrecognised, leading to underestimation of the disease prevalence⁸.

While many of the epidemiological studies to date have been conducted in cohorts of European origin, studies in other ancestries have highlighted population differences at specific RED loci^9–11. Among the most common REDs, myotonic dystrophy type 1 (DM1) affects 1 in 8,000 people worldwide¹², ranging from 1 in 10,000 in Iceland to 1 in 100,000 in Japan¹³. Similarly, HD prevalence ranges from 0.1 in 100,000 in Asian and African countries^14,15 to 10 in 100,000 in Europeans¹⁶. In Europeans, it is estimated that the prevalence of C9orf72-FTD is 0.04-134 in 100,000, and C9orf72-ALS is 0.5-1.2 in 100,000⁴. The spinocerebellar ataxias (SCAs) are a group of rare neurodegenerative disorders mainly affecting the cerebellum. They are individually rare worldwide, with largely variable frequencies among populations¹⁷, mainly due to founder effects. Overall, the worldwide prevalence of SCAs is 2.7-47 cases per 100,000¹⁰ with SCA3 being the most common form worldwide, followed by SCA2, SCA6, and SCA1¹⁸.

With the advent of disease-modifying therapies for REDs, it is becoming necessary to determine comprehensively the number of patients and type of RED expected in different populations, so that targeted approaches can be developed accordingly. Large-scale genetic analyses of REDs have been limited by repeat expansion profiling techniques, which historically have relied on polymerase chain reaction-based (PCR) assays or Southern blots, which by nature are targeted assays and can be difficult to scale. So far, the largest population study of the genetic frequency REDs involved the PCR-based analysis of 14,196 individuals of European ancestry¹⁹.

In the last few years, bioinformatic tools have been developed to profile DNA repeats from short-read whole exome²⁰ and whole genome sequencing data (WGS)²¹. We have recently shown that disease-causing repeat expansions can be detected from WGS with high sensitivity and specificity, making large-scale WGS datasets an invaluable resource for the analysis of the frequency and distribution of REDs⁷. Our group has previously applied this pipeline to a large WGS cohort to assess the distribution of repeat expansions in the AR gene, which cause Spinal and Bulbar Muscular Atrophy (SBMA), and found an unexpectedly high frequency of pathogenic alleles, suggesting under-diagnosis or incomplete penetrance of this RED²². However, a comprehensive study of REDs in the general population and across different ancestries using WGS has never been performed.

In the present study, we used large-scale genomic databases to address two main questions: i) what is the frequency of RED mutations in the general population? ii) how does the frequency and distribution of REDs vary across populations?

RESULTS

RED mutation frequency

To estimate the number of individuals carrying premutation or full mutation alleles (Table 1), we selected repeats in RED genes²⁷ for which WGS can accurately discriminate between normal and pathogenic alleles⁷, based on either or both, of the following conditions: the threshold between premutation and full mutation is shorter than the sequencing read-length (and therefore WGS can accurately distinguish between premutation and full mutation), or WGS was validated against the current gold-standard PCR test (Extended data Fig. 3, Table S3). For the latter, PCR tests were obtained from a cohort of individuals recruited to the 100K GP who had RED testing as part of their standard diagnostic pathway (Table S4, Methods). Within this dataset, we show that: i) WGS accurately classifies alleles in the normal, premutation, and full mutation range in all loci assessed except FMR1 (that causes Fragile X syndrome) (Extended data Fig. 3A, Table S4); ii) the accuracy of repeat sizing by WGS is not affected by genetic ancestry by comparing genotypes generated by WGS to PCR from different populations (Extended data Fig. 3B) but it might underestimate the size of large expansions in FMR1, DMPK, FXN, and C9orf72, as previously described⁷.

View this table:

• View inline
• View popup
• Download powerpoint

Table 1

Furthermore, as we previously developed and validated a dedicated WGS analytical workflow for the repeat expansion in RFC1 that causes CANVAS²⁸, this repeat was included in our analysis.

Overall, 16 RED loci pass our criteria for accurately estimating premutation and full mutation carrier frequencies, representing a broad spectrum of REDs and different modes of inheritance: 1) autosomal dominant: HD, Huntington disease-like 2 (HDL2), DM1, C9orf72-ALS/FTD, the spinocerebellar ataxias (SCA1, SCA2, SCA3, SCA6, SCA7, SCA12, SCA17), dentatorubral-pallidoluysian atrophy (DRPLA), and NOTCH2NLC, which causes a spectrum of neurological disorders, especially neuronal intranuclear inclusion disease and oculopharyngodistal myopathy; 2) autosomal recessive: Friedreich ataxia and CANVAS, 3) X-linked SBMA (Table 1).

Our analysis workflow (Fig. 1) included profiling each RED locus, followed by quality control of all alleles (employing Expansion Hunter classifier, https://github.com/bharatij/ExpansionHunter_Classifier, and visual inspection of pileup plots as previously described²⁹) predicted to be larger than the premutation threshold (Table S5, Methods). We also retrospectively analysed factors potentially leading to overestimating disease allele frequency, such as checking that there was no selection bias for patients with DM1 which can cause cardiac abnormalities (Table S6).

• Download figure
• Open in new tab

Figure 1.

A) List of RED loci included in the study including repeat-size thresholds for reduced penetrance and full mutations. B) Technical flowchart. Whole genome sequences (WGS) from the 100K GP and TOPMed datasets were first selected by excluding those associated with neurological diseases. WGS data from the 1K GP3 were also selected by having the same technical specifications (see Methods). After inferring ancestry prediction, repeat sizes for all 22 REDs were computed by using EH v3.2.2. On one hand, for 16 REDs overall carrier frequency, disease modelling, and correlation distribution of long normal alleles were computed in the 100K GP and TOPMed projects. On the other hand, the distribution of repeat sizes across different populations was analysed in the 100K GP and TOPMed combined, and in the 1K GP3 cohorts.

In total, for autosomal dominant and X-linked REDs, there were 290 individuals carrying one fully expanded repeat and 1,279 individuals carrying one repeat in the premutation range, meaning that the frequency of individuals carrying full-expansion and premutation alleles among this large cohort is 1 in 283 and 1 in 64, respectively (Table S7).

The most common expansions (in the full-mutation range, Table 1) were those in C9orf72 (C9orf72-ALS/FTD) and DMPK (DM1) with a frequency of 1 in 839 and 1 in 1,786 respectively, followed by expansions in AR (SBMA: 1 in 2,561 males) and HTT (HD: 1 in 4,109). Surprisingly, many individuals were found to carry expansions in the SCA genes: 1 in 5,136 in ATXN2 (SCA2), 1 in 5,136 in CACNA1A (SCA6), and 1 in 6,321 in ATXN1 (SCA1). By contrast, expansions in ATXN7 (SCA7) and TBP (SCA17) were present in only two individuals at each locus (1 in 41,077, and expansions in JPH3 (Huntington disease-like 2) and ATN1 (DRPLA) were very rare, with only a single individual at each locus identified with a repeat allele in the pathogenic full-mutation range. No pathogenic full-mutation expansions were identified in ATXN3 (SCA3), PPP2R2B (SCA12), and NOTCH2NLC (Fig. 2, Table S7).

• Download figure
• Open in new tab

Figure 2.

Forest plot with combined overall disease allele carrier frequency in the combined 100K GP and TOPMed datasets N = 82,176 (N individuals may vary slightly between loci due to data quality and filtering, See Table S7). The squares show the estimated disease allele carrier frequency, and the bars show the 95% CI values. Details of the statistical models are described in the Methods section. Grey and black boxes show premutation/reduced penetrance and full mutation allele carrier frequencies for each dominant locus, respectively. Grey and black boxes show mono-and bi-allelic carrier frequencies for recessive loci (RFC1 and FXN), respectively.

For autosomal recessive REDs, we found a carrier frequency (i.e. people that carry one expanded allele) of 1 in 101 for FXN (FA) and 1 in 14 for RFC1; and a frequency of biallelic expansions of 1 in 82,176 for FXN (FA) and 1 in 712 for RFC1 CANVAS (Fig. 2, Table S8). Demographic data available on all individuals carrying a pathogenic full-mutation repeat are listed in Table S9. The distribution of repeat sizes overall in this cohort is represented in Extended data Fig. 4.

Modelling the expected number of people affected by REDs

REDs have variable age at onset, disease duration, and penetrance¹. Therefore, the mutation frequency cannot be directly translated into disease frequency (i.e. prevalence). To estimate the expected number of people affected by REDs, we took the mutation frequency of the most common REDs (C9orf72-ALS/FTD, DM1, HD, SCA1, SCA2, SCA6), and modelled the distribution by age of those expected to be affected by REDs in the UK population. For this analysis, we used the data from the Office of National Statistics³⁰, and age of onset, penetrance, and impact on survival of each RED based on either cohort studies or disease-specific registries (Methods).

We estimated on average a two-to three-fold increase in the predicted number of people with REDs, compared to currently reported figures based on clinical observation, depending on the RED (Fig. 3). Since C9orf72 expansions cause both ALS and FTD, we modelled both diseases separately, providing for C9orf72-ALS an expected number of people affected over two times higher than previous estimates (Table S10: 1.8 per 100,000 versus 0.5-1.2 in 100,000^4,31) and for C9orf72-FTD 6.5 per 100,000 (Table S11) within the wide reported range^32,33). For DM1, we estimated that 15.9 per 100,000 people would be affected by the condition (Table S12), 1.3 times higher than the estimated prevalence from clinical data (12.25 in 100,000³⁴). For HD, the majority of individuals with a pathogenic expansion in our cohort carries alleles with 40 repeats (12 out of 20 people, Table S9). Given the well-established relationship between HTT repeat length and age at onset, we modelled the expected number of people with HD based on the observed frequency of the expansion, taking into account age at onset distribution and penetrance data for repeat length equal to 40 units⁶. We found that 2.3 per 100,000 people are estimated to have HD caused by 40 CAG repeats (Table S13): over 3 times higher than the reported number of affected patients with 40 CAG repeats (0.72 per 100,000; Methods and personal communication, DRL and DHM). For SCA2 and SCA1 our model indicates over three-fold increase in the number of people expected with the disease compared to the reported prevalence (3 and 3.7 per 100,000 respectively based on our estimate in Table S14, Table S15 versus the currently reported prevalence of 1 per 100,000)^35,36. Strikingly, we found that the expected number of people with SCA6 would be nine times higher than the reported prevalence: 9 in 100,000 versus 1 in 100,000 individuals (Table S16, Methods). Overall, these data indicate that REDs are either underdiagnosed or that not all individuals who carry a repeat larger than the established full mutation cut-off develop the condition (i.e. incomplete penetrance).

• Download figure
• Open in new tab

Figure 3.

Flowchart showing the modelling of disease prevalence by age for C9orf72-ALS, C9orf72-FTD, HD in 40 CAG repeat carriers, SCA2, DM1, SCA1, and SCA6. UK population count by age is multiplied by the combined disease allele frequency of each genetic defect and the age of onset distribution of each corresponding disease, and corrected for median survival. Penetrance is also taken into account for C9orf72-ALS and C9orf72-FTD. Estimated number of people affected by REDs (dark blue area) compared to the reported prevalence from the literature (light blue area). Age bins are 5 years each. For C9orf72-FTD, given the wide range of the reported disease prevalence,^32,33 both lower and upper limits are plotted in light blue.

RED mutation frequency in different populations

The prevalence of individual REDs varies considerably based on geographic location. Hence, we set out to analyse whether these differences are reflected in the broad genetic ancestries of our cohort. First, we visualised the individuals carrying an expansion in a RED gene on the principal component analysis plot (Extended data Fig. 5). We then computed the proportion of pathogenic allele carriers (premutation and full mutation allele carriers) in each population (Fig. 4A, Table S17). In agreement with current known epidemiological studies, we observed that pathogenic alleles in FXN (FA), C9orf72, and DMPK (DM1) are more common in European; those in ATN1 (DRPLA), TBP (SCA17), and in NOTCH2NLC are more common in East Asians, and those in JPH3 (HDL2) are more common in Africans. Conversely, pathogenic alleles in ATXN2 are more equally distributed across different populations, and those in RFC1 are less prevalent in Africans. Moreover, pathogenic expansions within C9orf72 and HTT were identified in Africans and South Asians, which to date have only been reported in smaller clinical studies^11,37–40. Given that the initial ancestry assignments for our cohort were based on genome-wide data, we performed local ancestry analysis to check for admixture in these individuals, confirming that the expanded repeat alleles segregated on haplotypes of African and South Asian ancestry (Methods).

• Download figure
• Open in new tab

Figure 4.

Pathogenic RED frequencies in different populations (African = 12,786; American = 5,674; East Asian = 1,266; European = 59,568; South Asian = 2,882. A) Forest plot of pathogenic allele carrier frequency divided by population. Pathogenic alleles are defined as those larger than the premutation cut-off (Table1). Data are presented as squares showing the estimated pathogenic allele carrier frequency, and bars showing the 95% CI values. B) Bar chart showing the proportion of pathogenic allele carrier frequency repeats by ancestry. Both plots have been generated by combining data from 100K GP and TOPMed from a total of N = 82,176 unrelated genomes. N individuals may vary slightly between loci due to data quality and filtering, see Table S17 and Table S18).

• Download figure
• Open in new tab

Figure 5.

Distribution of repeat lengths in different populations. A) Half-violin plots showing the distribution of alleles in different populations (African = 12,786; American = 5,674; East Asian = 1,266; European = 59,568; South Asian = 2,882) for 10 loci (Methods) from the combined 100K GP and TOPMed cohorts. Box plots highlight the interquartile range and median, and black dots show values outside 1.5 times the interquartile range. Red dots mark the 99.9^th percentile for each population and locus. Vertical bars indicate the intermediate and pathogenic allele thresholds (Table S20). B) Scatter plot shows the frequency of intermediate allele carriers (x-axis) against the frequency of pathogenic allele carriers (y-axis). Data points are divided by population (n=5) and gene (n=10), and size represents the total number of intermediate alleles. Correlations were computed using the Spearman method, and two-tailed p-values.

We then analysed the relative frequency of pathogenic allele carriers within each population (Fig. 4B, Table S18), highlighting differences in the proportion of REDs within and between populations. Pathogenic allele carriers were observed in most REDs across all populations (e.g. those in AR, ATXN1, ATXN2, HTT and TBP), though in variable proportions and with some notable exceptions. Pathogenic alleles in RFC1 are by far the most widely represented (followed by those in AR and TBP). The African population is the most diverse, with pathogenic expansions present across all RED loci, except CACNA1A. The East Asian population is the one with more striking differences in the relative frequency of REDs, and notably the absence of pathogenic alleles in FXN and DMPK and the large proportion of TBP (signal driven mainly reduced penetrance alleles; Table S7 shows that the carrier frequency of reduced penetrance alleles).

Distribution of repeat lengths in different populations

REDs are thought to arise from large normal polymorphic repeats (large normal, or “intermediate” range repeats), as they have an increased propensity to further expand upon transmission from parent to progeny, moving into the pathogenic range. The uneven RED prevalence across major populations has been associated with the variable frequency of intermediate alleles^41,42.

Therefore, we analysed intermediate allele frequencies for those genes where WGS can accurately size intermediate alleles (Methods) across populations and confirmed that: i) the overall distribution of repeat lengths varies across populations (Fig. 5A, Extended data Fig. 6, Table S19); for example, the median repeat size of PPP2R2B is higher in East and South Asians compared to Europeans (13 versus 10 repeats); ii) overall, the frequency of intermediate alleles varies in each population, and correlates with the frequency of pathogenic alleles; (R = 0.65; p = 3.1×10^-7, Spearman correlation) (Fig. 5B, Extended data Fig. 7, Table S20). These data suggest that different distributions of repeat lengths underlie differences in the epidemiology of REDs.

In fact, for HD^43,44, specific structures have been proposed as cis-acting modifiers of HD³⁹. In a typical HTT allele, the pure CAG tract (Q1) is followed by an interrupting CAACAG sequence (Q2). These are followed by a polyproline region encoded by a CCGCCA sequence (P1), then by stretches of CCG repeats (P2), and, lastly, by CCT repeats (P3) (Fig. 6A). Variations in this sequence have been described, including duplication or loss of Q2 or loss of P1, and variation in the number of the downstream P2 and P3 repeats. To analyse population differences in the repeat structures of HTT, we developed an analytical workflow to determine accurately phased Q1, Q2, and P1 elements of the HTT structure from WGS (Methods). We confirm that the typical structure Q1_n-Q2₁-P1₁ (also known as ‘canonical’) is the most common across populations, and that other structures are present in different proportions in different populations: P1 loss alleles are more prevalent in Africans and East Asians; while overall non-canonical alleles are more frequent in African, p < 0.0001 two-tailed Chi-square test) (Fig. 6B). Moreover, variable Q1 repeat lengths are associated with different structures (linear model, p-value <2.2×10^-16): shorter Q1 lengths are found on chromosomes with Q2 duplication, and larger Q1 lengths are found in those with Q2 loss and Q2-P1 loss (Fig 6C).

• Download figure
• Open in new tab

Figure 6.

HTT repeat structures show varied prevalence across genetic ancestries and are associated with CAG repeat size. A) Allele structures observed within exon 1 of HTT. The CAG repeat is denoted as “Q1” and marked in gold. The CAACAG unit is referred to as “Q2” and is marked in green. The first proline-encoding “CCGCCA” repeat element is referred to as “P1” and is marked in purple. B) The prevalence of the allele structures is plotted across the studied genetic ancestries in bar plots on the x-axis. The ancestries are defined on the y-axis. The number of alleles in each of the genetic ancestries is denoted as “N=…” at each of the y-axis ticks. C) Boxplots display the distribution of CAG repeat sizes across different repeat structures. Box plots highlight the median (horizontal lines in the centre of each boxplot), interquartile range (bounds) and black dots show values outside 1.5 times the interquartile range. The repeat structures are separated on the x-axis and the repeat size is shown on the y-axis. The number of alleles with different repeat structures is denoted as “N=…” on the x-axis. A linear model was used to compare the repeat size distribution of the canonical alleles versus that of all atypical structures. Kruskal-Wallis tests with Dunn’s correction for multiple comparisons p value; p-values resulting from pairwise tests are displayed above each structure (*** < 0.001; * < 0.05). Q2 versus canonical (p-value = 6.4×10^{- 32}), Q2 versus partialQ2 loss (p-value = 3.5×10^-2), Q2 duplication versus P1 loss (p-value = 5.9×10^-98), Q2 duplication versus Q2 loss (p-value = 8.5×10^-16); Q2 duplication versus Q2-P1 loss (p-value = 6.2×10^-20), canonical versus P1 loss (p-value = 2.4×10^{- 80}), canonical versus Q2 loss (p-value = 2.8×10^-8), canonical versus Q2-P1 loss (p value = 1.2×10¹²), P1 loss versus Q2 loss (p-value = 2.8×10^-2), P1 loss versus vs Q2-P1 loss (p-value = 5.6×10^-6)

DISCUSSION

By analysing a cross-sectional cohort of 82,176 people, this study provides the largest population-based estimate of disease allele carrier frequency and RED distribution in different populations. We show that: i) the disease allele carrier frequency of REDs is approximately ten times higher than the previous estimates based on clinical observations, and that, based on population modelling, REDs would be predicted to affect, on average, two to three times more individuals than are currently recognised clinically; ii) while some REDs are population-specific like JPH3 (HDL2), the majority are observed in all ancestral populations, challenging the notion that some REDs are associated with population-specific founder effects (e.g. C9orf72); iii) the different distribution of repeat lengths between population broadly reflects the known differences in disease epidemiology; iv) an appreciable proportion of the population carry alleles in the premutation range, and are therefore at risk of having children with REDs.

As the cohort in which we carried out this study was collected for medical sequencing purposes, we controlled for factors potentially leading to overestimating disease allele carrier frequency, such as excluding people and their relatives with neurological disorders, and checking that there was no selection bias for patients with DM1 (Table S6) which can cause cardiac abnormalities. Our estimates for DM1 and SCAs match those previously reported using PCR-based approaches to determine the genetic prevalence of REDs^8,19,46, confirming the accuracy of our results.

Different factors might explain the discrepancy between the increased number of people carrying disease alleles in our cohort compared with known RED epidemiology. First, our estimates are based on large admixed cohorts, as opposed to epidemiological studies based on clinically affected individuals in smaller populations. As REDs have variable clinical presentation and age at onset, individuals with REDs may remain undiagnosed in studies in which estimates of disease frequency rely on clinical ascertainment of patients. Notably, the first descriptions of the clinical phenotype of RED were based on families collected for linkage studies with an intrinsic ascertainment bias for more severe disease manifestations, resulting in a lack of very mild cases in the phenotypic spectrum. Because of the wide spectrum of milder phenotypic presentations of REDs, the prevalence of these diseases might have been underestimated. This might be true particularly for milder forms of the disease spectrum, like DM1 for example: it is well documented that carriers of small DMPK expansions (50–100 repeats) have a milder disease with clinical features that may go unnoticed, especially early in their disease course⁴⁷. In fact, we observed a large number of individuals carrying repeats in the lower end of the pathogenic range (e.g. HTT, ATXN2, and DMPK; Table S9).

On the other hand, prevalence studies are only based on individuals with manifest disease, leading to a potential bias in the disease penetrance from those who have not developed the illness. It is believed that the penetrance of REDs is characterised by a threshold effect, with people carrying an allele above a particular repeat length certainly developing the disease, as opposed to those carrying shorter repeats. Given the relationship between the size of the repeat expansion and the disease onset and progression, it is possible that individuals carrying alleles currently classified as fully penetrant (e.g. ≥40 CAG repeats in HTT) may sometimes remain asymptomatic. In this regard, previously published studies on HD⁶ and SBMA⁴⁸ have suggested incomplete penetrance of repeats in the lower end of the pathogenic range.

Finally, these individuals may carry genetic modifiers of REDs, such as interspersions. We visually inspected all alleles in the pathogenic range and did not identify atypical sequence structures within the expanded repeat. Accordingly, in HTT, where we performed a dedicated structural analysis (Fig. 6), all individuals carrying a fully expanded repeat show a typical canonical structure.

The finding that a much larger number of people in the general population carry pathogenic alleles of REDs has important implications both for diagnosis and genetic counselling of RED. For diagnosis, when a patient presents with symptoms compatible with a RED, clinicians should have a higher index of suspicion of these diseases, and clinical diagnostic pathways should facilitate genetic testing for REDs. Currently, genetic testing for REDs tends to be a PCR-based targeted assay, with clinicians suspecting a RED ordering a test for a specific gene. As REDs are clinically and genetically heterogeneous with a tendency to have overlapping features, REDs may remain undiagnosed. The wider use of WGS and the advent of genetic technologies such as long-read sequencing can potentially address this by simultaneously interrogating an entire panel of RED loci⁴⁹. The broader availability of such diagnostic tools would increase the diagnostic rate for REDs, thus closing the gap between disease incidence rates and estimates based on population genetic sequencing. As for genetic counselling, when a RED expansion is identified incidentally in an individual clinically unaffected, it would be important to address the potentially incomplete penetrance of the repeat, especially for small expansions. Further studies both in clinically affected individuals and in large clinical and genomic datasets from the general population are needed to address the full clinical spectrum and the penetrance by repeat sizes.

Our results are concordant with current epidemiological studies about the relative frequency of REDs, with the most common being DM1 and C9orf72-ALS/FTD (autosomal dominant) and CANVAS and sensory neuropathy (recessive). One exception is ATXN3, the most commonly reported SCA locus in patients affected by spinocerebellar ataxia, which was absent in our cohort. This might be due to either a recruitment bias, with individuals with overt REDs having a reduced likelihood of being recruited to such studies because of the severity of their disease (TOPMed cohort), or to the fact that there are no or very few premutation alleles (0 in 59,568 Europeans), indicating that the expansion mutation is linked to few rare ancestral haplotypes⁵⁰, rather than being a gradual process arising from common large normal alleles like other REDs.

The presence of rare expansions of REDs previously thought to occur only in Europeans (e.g. C9orf72) in African and Asian populations supports diagnostic testing for them in people presenting with features of ALS-FTD independently of their ethnicity. The lowest observed rates of some REDs in some populations (for example, FXN and DMPK in East Asians), consistent with known epidemiological studies, might be due to reduced mutation rates. Further research is needed to study the potential role of population-specific cis and trans genetic modifiers of repeat expansion mutations, that underlie the marked global differences in prevalence found in the present study.

One limitation of this study is that WGS cannot accurately size repeats larger than the sequencing read length, and it is therefore not possible to accurately estimate the disease allele frequency of all RED loci. Of the 46 RED loci that have been linked to human disease²⁷, we included all loci where it is technically possible to address our questions: 1) to accurately estimate the disease allele carrier frequency 16 REDs were selected; 2) to analyse the distribution of repeat lengths in different populations 6 further REDs were selected, covering a total of 22 RED loci, and providing the basis for the different prevalence of REDs in different populations. RED loci that are not included are those caused by an insertion of a non-reference sequence (currently there is no validated pipeline that can accurately size and sequence large repeat expansions in such loci, except RFC1), and those caused by non-pure sequences e.g. “GCN” motifs (caused by a different mutational mechanism, namely unequal allelic homologous recombination)⁵¹. We note that many newly discovered REDs are caused by large expansions⁵²: only a broader availability of long-read sequencing technologies will facilitate addressing important questions about the frequency of these mutations.

Both 100K GP and TOPMed datasets are Euro-centric, comprising over 62% of European samples. TOPMed is more diverse, with 24% and 17% of African and American genomes respectively, which are only present at 3.2% and 2.1% frequency in the 100K GP. East and South Asian backgrounds are underrepresented in both datasets, limiting the ability to detect rarer repeat expansions in these populations. Further analyses on more heterogeneous and diverse large-scale WGS datasets are necessary not only to confirm our findings but also to shed light on additional ancestries. With regard to this, there are multiple ongoing projects with Asian populations⁵³. Countries including China, Japan, Qatar, Saudi Arabia, India, Nigeria, and Turkey have all launched their own genomics projects during the last decade⁵⁴. Analysing genomes from these programmes will yield more detail on the prevalence of REDs around the world.

Despite efforts to estimate the frequency of REDs globally and locally, there is uncertainty surrounding their true prevalence, limiting the knowledge of the burden of disease required to secure dedicated resources to support health services, such as the estimation of the numbers of individuals profiting from drug development and novel therapies, or participating in clinical trials. There are currently no disease-modifying treatments for REDs; however, both disease-specific treatments and drugs which target the mechanisms leading to repeat expansions are in development. We have established that the number of people who may benefit from such treatments is greater than previously thought.

Funding

Medical Research Council, Department of Health and Social Care, National Health Service England, National Institute for Health Research

Authors’ contribution statement

K.I. and A.T. conceptualised the research project. K.I., B.J. M.Z., D.G. C.C., S.F., P.G, L.M., M.S., V.E.P., A.T. A.J.S, conducted data analysis, interpreted statistical findings and created visual representations of the data. K.I., B.J., M.Z., P.G., A.M.T., S.J.G., V.G.D., D.J.H.M, C.R., A.T. performed quality check visually inspecting pileup plots corresponding to repeat expansions. J.V. analysed the carrier frequency for RFC1 within the 100K GP. C.M.B., H.W., C.T., S.T., J.D.L and D.R.L. provided data from HD and DM1 patient registries. A.C. provided valuable insights into the genetics of RFC1. Funding and supervision: A.T., A.J.S., P.F., M.J.C., J.H, H.H. Writing—original draft: K.I., A.T., A.J.S., A.D., D.J.H.M., M.Z., C.R., and M.S. meticulously reviewed and edited the manuscript for clarity, accuracy, and coherence. All authors carefully reviewed the manuscript, offering pertinent feedback that enhanced the study’s quality, and ultimately approved the final version.

Competing Interests Statement

The authors declare no competing interests

Methods

Computation of genetic prevalence

The frequency of each repeat size across the 100K GP and TOPMed genomic datasets was determined. Genetic prevalence was calculated as the number of genomes with repeats exceeding the premutation and full mutation cut-offs (Table 1) for autosomal dominant and X-linked REDs (Table S7); for autosomal recessive REDs, the total number of genomes with monoallelic or biallelic expansions was calculated, compared to the overall cohort (Table S8).

Overall unrelated and non-neurological disease genomes corresponding to both programmes were considered, breaking down by ancestry.

CARRIER FREQUENCY ESTIMATE (1 in x)

- freq_carrier = round(total_unrel / total_exp_after_VI_locus, digits = 0) where

- ‘total_unrel’ is the total number of unrelated genomes

- ‘total_exp_after_VI_locus’ is the total number of genomes that have a repeat expansion beyond premutation or full-mutation after visual inspection (per each locus)

CONFIDENCE INTERVALS:

- n = total number of unrelated genomes

- p = total expansions / total number of unrelated genomes

- q = 1 - p

- z = 1.96

PREVALENCE ESTIMATE (x in 100,000)

x = 100,000/freq_carrier new_low_ci = 100000*ci_max_final new_high_ci = 100000*ci_min_final

Modelling disease prevalence using carrier frequency

The total number of expected people with the disease caused by the repeat expansion mutation in the population (𝑀) was estimated as: where 𝑀, is the expected number of new cases at age 𝑘 with the mutation and 𝑛 is survival length with the disease in years.

𝑀, is estimated as 𝑀, = 𝑓 ∗ 𝑁, ∗ 𝑝, where 𝑓 is the frequency of the mutation, 𝑁, is the number of people in the population at age 𝑘 (according to Office of National Statistics, ONS⁸), and 𝑝, is the proportion of people with the disease at age 𝑘, estimated at the number of the new cases at age 𝑘 (according to cohort studies and international registries) divided by the total number of cases.

To estimate the expected number of new cases by age group, the age at onset distribution of the specific disease, available from cohort studies or international registries, was used. For C9orf72-disease, we tabulated the distribution of disease onset of 811 patients with C9orf72-ALS pure and overlap FTD, and 323 patients with C9orf72-FTD pure and overlap ALS²². HD onset was modelled using data derived from a cohort of 2,913 individuals with HD described by Langbehn et al.²³; and DM1 was modelled on a cohort of 264 non-congenital patients derived from the UK Myotonic Dystrophy patient registry²⁴. Data from 157 patients with SCA2 and ATXN2 allele size equal to or higher than 35 repeats from EUROSCA were used to model the prevalence of SCA2²⁵. From the same registry, data from 91 patients with SCA1 and ATXN1 allele sizes equal to or higher than 44 repeats and of 107 patients with SCA6 and CACNA1A allele sizes equal to or higher than 20 repeats were used to model disease prevalence of SCA1 and SCA6, respectively.

As some REDs have reduced age-related penetrance, e.g. C9orf72-carriers may not develop symptoms even after 90 years of age²², age-related penetrance was obtained as follows: as regards C9orf72-ALS/FTD, it was derived from the red curve in Fig.2 (data available at https://github.com/nam10/C9_Penetrance) reported by Murphy et al²² and was used to correct C9orf72-ALS and C9orf72-FTD prevalence by age. For HD, age-related penetrance for a 40 CAG repeat carrier was provided by DRL, based on his work²³.

DETAILED DESCRIPTION OF THE METHOD THAT EXPLAINS TABLE S10-S16:

Both the general UK population and age at onset distribution of each disease were tabulated (Tables S10-S16, column B and column C). After standardisation over the total number (Tables S10-S16, column D), the onset count was multiplied by the carrier frequency of the genetic defect (Tables S10-S16, column E) and then multiplied by the corresponding general population count for each age group, to obtain the estimated number of people in the UK developing each specific disease by age group (Tables S10-S11, column G, Tables S12-S16 column F). This estimate was further corrected by the age-related penetrance of the genetic defect where available (e.g., C9orf72-ALS and FTD) (Tables S10-S11, columns F). Finally, to account for disease survival, we performed a cumulative distribution of prevalence estimates grouped by a number of years equal to the median survival length for that disease (Tables S10-S11, column H, Tables S12-S16 column G). The median survival length (𝑛) used for this analysis is: 3 years for C9orf72-ALS⁹, 10 years for C9orf72-FTD⁹, 15 years for HD¹⁴ (40 CAG repeat carriers), 15 years for SCA2 and for SCA1¹⁸; for SCA6 normal life expectancy was assumed. For DM1, since life expectancy is partly related to the age of onset, the mean age of death was assumed to be 45 years for patients with childhood onset and 52 years for early adult-onset patients (10-30 years)²⁶, while no age of death was set for DM1 patients with onset after 31 years. Since survival is approximately 80% after 10 years²⁰, we subtracted 20% of the predicted affected individuals after the first 10 years. Then, survival was assumed to proportionally decrease in the following years until the mean age of death for each age group was reached.

The resulting estimated prevalences of C9orf72-ALS/FTD, HD, SCA2, DM1, SCA1, and SCA6 by age group were plotted in Fig.3 (dark blue area). The literature reported prevalence by age for each disease was obtained by dividing the new estimated prevalence by age by the ratio between the two prevalences, and represented as a light blue area.

To compare the new estimated prevalence to the clinical disease prevalence reported in the literature for each disease, we employed figures calculated in European populations, as it is closer to the UK population in terms of ethnic distribution:

i) C9orf72-FTD: the median prevalence of FTD was obtained from studies included in the systematic review by Hogan and colleagues¹² (83.5 in 100,000). Since 4-29% of FTD patients carry a C9orf72 repeat expansion¹³, we calculated C9orf72-FTD prevalence by multiplying this proportion range by median FTD prevalence (3.3 - 24.2 in 100,000, mean 13.78 in 100,000); ii) C9orf72-ALS: The reported prevalence of ALS is 5-12 in 100,000¹⁰ and C9orf72 repeat expansion is found in 30%-50% of individuals with familial forms and in 4%-10% of people with sporadic disease¹¹. Given that ALS is familial in 10% of cases and sporadic in 90%, we estimated the prevalence of C9orf72-ALS by calculating the [(0.4 of 0.1) + (0.07 of 0.9)] of known ALS prevalence of 0.5-1.2 in 100,000 (mean prevalence is 0.8 in 100,000); iii) HD prevalence ranges from 0.4 in 100,000 in Asian countries¹⁵ to 10 in 100,000 in Europeans¹⁶, and the mean prevalence is 5.2 in 100,000. 40-CAG repeat carriers represent 7.4% of patients clinically affected by HD according to the Enroll-HD¹⁷ version 6. Considering an average reported prevalence of 9.7 in 100,000 Europeans, we calculated a prevalence of 0.72 in 100,000 for symptomatic 40-CAG carriers; iv) DM1 is much more frequent in Europe than in other continents, with figures of 1 in 100,000 in some areas of Japan²⁷. A recent meta-analysis has found an overall prevalence of 12.25 per 100,000 individuals in Europe, which we used in our analysis²¹.

Given that the epidemiology of autosomal dominant ataxias varies among countries¹⁹ and no precise prevalence figures derived from clinical observation are available in the literature, we approximated SCA2, SCA1, and SCA6 prevalence figures to be equal to 1 in 100,000.

Data availability

For the 100K GP, full data is available in the Genomic England Secure Research Environment. Access is controlled to protect the privacy and confidentiality of participants in the Genomics England 100,000 Genomes Project and to comply with the consent given by participants for use of their healthcare and genomic data. Access to full data is permitted through the Research Network (https://www.genomicsengland.co.uk/research/academic/join-research-network).

For TOPMed, a detailed description of the TOPMed participant consents and data access is provided in Box 1¹. TOPMed data used in this manuscript are available through dbGaP. The dbGaP accession numbers for all TOPMed studies referenced in this paper are listed in Extended Data Tables 23¹. A complete list of TOPMed genetic variants with summary level information used in this manuscript is available through the BRAVO variant browser (bravo.sph.umich.edu). The TOPMed imputation reference panel described in this manuscript can be used freely for imputation through the NHLBI BioData Catalyst at the TOPMed Imputation Server (https://imputation.biodatacatalyst.nhlbi.nih.gov/). DNA sequence and reference placement of assembled insertions are available in VCF format (without individual genotypes) on dbGaP under the TOPMed GSR accession phs001974.

For the 1000 Genomes Project, the WGS datasets are available from the European Nucleotide Archive under accessions PRJEB31736 (unrelated samples) and PRJEB36890 (related samples).

Code availability

The following GitHub repositories used in this work are free to access:

- Expansion Hunter v3.2.2 (to estimate the repeat size within defined loci): https://github.com/Illumina/ExpansionHunter

- REViewer v0.2.7 (to generate pileup plots for quality check): https://github.com/Illumina/REViewer

- ExpansionHunter_Classifier (March 2024 release, to automatically run quality assessment of EHv322 call): https://github.com/bharatij/ExpansionHunter_Classifier

- Code to analyse repeat structure across HTT: https://github.com/chrisclarkson/gel/tree/main/HTT_work

- gvcfgenotyper (to merge gVCF files, when inferring ancestry across genomes within the 100K GP and TOPMed datasets): https://github.com/Illumina/gvcfgenotyper

- To compute survival curve analysis for C9orf72: https://github.com/nam10/C9_Penetrance